glp-1 ras mechanism Receptor Agonists as Treatments for Type 2 Diabetes A Closer Look at the

The only head-to-head trial (SURPASS-2) compared tirzepatide to semaglutide 1 mg for diabetes and found tirzepatide better for both HbA1c and weight

and by the Mann-Whitney test for b and c

Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial

You can also use the chatbot on this page for a free case evaluation

For context, licensed GLP-1 receptor agonists used in weight management such as semaglutide 2.4 mg (Wegovy) cost in the region of 200300 per month when prescribed privately in the UK (indicative figures as of mid-2025

However, alongside these cardiovascular benefits, clinical trials and real-world observations have consistently noted a modest increase in resting heart rate among patients taking GLP-1 receptor agonists